A BUDGET IMPACT ANALYSIS TO ESTIMATE THE ECONOMIC CONSEQUENCES OF INTRODUCING THE COMBINATION OF AVASTIN + TARCEVA FOR THE TREATMENT OF FIRST LINE EPIDERMAL GROWTH FACTOR (EGFR) METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)

Author(s)

Orfanos P¹, Wright EJ², C. Munk V²
¹F. Hoffmann-La Roche Ltd., Basel, Switzerland, Basel, Switzerland, ²ROCHE, Basel, Switzerland

OBJECTIVES:

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

PCN65

Economic Evaluation

Budget Impact Analysis

Oncology

Explore Related HEOR by Topic